Temsirolimus

Generic Name: Temsirolimus

Brand Names: Torisel

Drug Type: Small Molecule

Chemical Formula: C_₅₆H_₈₇NO_₁₆

CAS Number: 162635-04-3

Unique Ingredient Identifier: 624KN6GM2T

Background: Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.

Indication: For the treatment of renal cell carcinoma (RCC). Also investigated for use/treatment in breast cancer, lymphoma (unspecified), rheumatoid arthritis, and multiple myeloma.

Associated Conditions: Advanced Renal Cell Carcinoma

Clinical Trials

Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma

Phase 4

Completed

Conditions: Non-Hodgkin's Lymphoma

Interventions: Drug: temsirolimus

First Posted Date: 2010-08-11

Last Posted Date: 2019-05-20

Lead Sponsor: Pfizer

Target Recruit Count: 101

Registration Number: NCT01180049

Locations: 🇷🇴
Spitalul Universitar de Urgenta Bucuresti, Clinica de Hematologie, Bucuresti, Romania
🇦🇺
Royal Hobart Hospital, Hobart, Tasmania, Australia
🇺🇸
Mercy Research Institute, Miami, Florida, United States

and more 27 locations

Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer

Phase 1

Terminated

Conditions: Adenocarcinoma of the Prostate
Hormone-resistant Prostate Cancer
Recurrent Prostate Cancer
Stage IV Prostate Cancer
Prostate Cancer

Interventions: Drug: vorinostat
Drug: temsirolimus
Other: laboratory biomarker analysis
Procedure: positron emission tomography/computed tomography

First Posted Date: 2010-08-03

Last Posted Date: 2022-10-03

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 13

Registration Number: NCT01174199

Locations: 🇺🇸
The Sydney Kimmel Comprehensive Center at John Hopkins, Baltimore, Maryland, United States
🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Bendamustine and Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Non-Hodgkin's Lymphoma (NHL)

Phase 1

Withdrawn

Conditions: Mantle Cell Lymphoma

First Posted Date: 2010-07-27

Last Posted Date: 2011-03-16

Lead Sponsor: Charite University, Berlin, Germany

Target Recruit Count: 20

Registration Number: NCT01170052

Locations: 🇩🇪
Dept. of Hematology and Oncology, Charité, Campus Virchow Klinikum Charité, Berlin, Germany
🇩🇪
Dept. of Hematology and Oncology, Charité, Campus Benjamin Franklin, Berlin, Germany
🇩🇪
Dept. of Hematology and Oncology, Charité, Campus Charité Mitte, Berlin, Germany

Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV

Phase 2

Terminated

Conditions: Mucosal Melanoma
Recurrent Melanoma
Stage IV Melanoma

Interventions: Drug: temsirolimus
Drug: selumetinib
Other: laboratory biomarker analysis

First Posted Date: 2010-07-20

Last Posted Date: 2014-05-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 4

Registration Number: NCT01166126

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors

Phase 1

Completed

Conditions: Recurrent Breast Cancer
Recurrent Cervical Cancer
Recurrent Endometrial Carcinoma
Stage III Neuroendocrine Carcinoma of the Skin
Stage III Ovarian Epithelial Cancer
Stage IV Endometrial Carcinoma
Stage IV Neuroendocrine Carcinoma of the Skin
Stage IV Non-small Cell Lung Cancer
Stage IVA Cervical Cancer
Recurrent Gastrointestinal Carcinoid Tumor

Interventions: Drug: temsirolimus
Drug: vinorelbine ditartrate

First Posted Date: 2010-07-01

Last Posted Date: 2016-06-13

Lead Sponsor: University of Southern California

Target Recruit Count: 19

Registration Number: NCT01155258

Locations: 🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States

Temsirolimus, Irinotecan Hydrochloride, and Temozolomide in Treating Younger Patients With Relapsed or Refractory Solid Tumors

Phase 1

Completed

Conditions: Unspecified Childhood Solid Tumor, Protocol Specific

Interventions: Drug: temsirolimus
Drug: temozolomide
Drug: irinotecan hydrochloride
Other: laboratory biomarker analysis

First Posted Date: 2010-06-10

Last Posted Date: 2014-04-10

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 72

Registration Number: NCT01141244

Locations: 🇨🇦
Hospital for Sick Children, Toronto, Ontario, Canada
🇺🇸
University of California San Francisco Medical Center-Parnassus, San Francisco, California, United States
🇺🇸
C S Mott Children's Hospital, Ann Arbor, Michigan, United States

and more 22 locations

Sunitinib Plus Temsirolimus in Patients With Renal Cell Cancer (RCC)

Phase 1

Completed

Conditions: Kidney Cancer
Renal Cell Cancer

Interventions: Drug: Sunitinib
Drug: Temsirolimus

First Posted Date: 2010-05-13

Last Posted Date: 2015-11-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 23

Registration Number: NCT01122615

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Drug: Temsirolimus
Drug: Neratinib

First Posted Date: 2010-04-28

Last Posted Date: 2018-09-26

Lead Sponsor: Puma Biotechnology, Inc.

Target Recruit Count: 99

Registration Number: NCT01111825

Locations: 🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇪🇸
Hospital Universitario Vall d'Hebron, Barcelona, Spain
🇺🇸
Western Regional Medical Center, Inc., Goodyear, Arizona, United States

and more 9 locations

Temsirolimus in Myelodysplastic Syndrome (MDS)

Phase 2

Terminated

Conditions: Myelodysplastic Syndrome

Interventions: Drug: Temsirolimus

First Posted Date: 2010-04-27

Last Posted Date: 2015-02-13

Lead Sponsor: Technische Universität Dresden

Target Recruit Count: 20

Registration Number: NCT01111448

Locations: 🇩🇪
Universitätsmedizin Göttingen Georg-August-Universität Abteilung Hämatologie und Onkologie, Goettingen, Germany
🇩🇪
Universitätsklinikum Düsseldorf Klinik für Hämatologie, Onkologie und Klin. Immunologie, Düsseldorf, Germany
🇩🇪
Universitätsklinikum Leipzig AöR, Leipzig, Germany

and more 4 locations

Gemcitabine Hydrochloride, Cisplatin, and Temsirolimus as First-Line Therapy in Treating Patients With Locally Advanced and/or Metastatic Transitional Cell Cancer of the Urothelium

Phase 1

Completed

Conditions: Bladder Cancer
Urethral Cancer
Transitional Cell Cancer of the Renal Pelvis and Ureter

First Posted Date: 2010-03-22

Last Posted Date: 2018-02-06

Lead Sponsor: Cardiff University

Target Recruit Count: 15

Registration Number: NCT01090466

Locations: 🇬🇧
Leeds Cancer Centre at St. James's University Hospital, Leeds, England, United Kingdom

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy